These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12651070)

  • 21. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens.
    Albiero E; Amati E; Baumeister E; Einsele H; Grigoleit GU; Rodeghiero F
    J Immunother; 2016; 39(9):329-342. PubMed ID: 27631893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
    Abu-Khader A; Krause S
    Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.
    La Rosa C; Wang Z; Brewer JC; Lacey SF; Villacres MC; Sharan R; Krishnan R; Crooks M; Markel S; Maas R; Diamond DJ
    Blood; 2002 Nov; 100(10):3681-9. PubMed ID: 12393676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
    Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
    Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
    Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
    Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
    Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
    Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
    J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of key peptide-specific CD4+ T cell responses to human cytomegalovirus: implications for tracking antiviral populations.
    Harcourt GC; Scriba TJ; Semmo N; Bounds S; Taylor E; Klenerman P
    Clin Exp Immunol; 2006 Nov; 146(2):203-10. PubMed ID: 17034571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.
    Hasan AN; Kollen WJ; Trivedi D; Selvakumar A; Dupont B; Sadelain M; O'Reilly RJ
    J Immunol; 2009 Aug; 183(4):2837-50. PubMed ID: 19635907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.
    Villacres MC; Lacey SF; La Rosa C; Krishnan R; Auge C; Longmate J; Zaia JA; Leedom JM; Diamond DJ
    J Infect Dis; 2001 Aug; 184(3):256-67. PubMed ID: 11443550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice.
    Lenfant F; Pizzato N; Liang S; Davrinche C; Le Bouteiller P; Horuzsko A
    J Gen Virol; 2003 Feb; 84(Pt 2):307-317. PubMed ID: 12560562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection.
    Gibson L; Piccinini G; Lilleri D; Revello MG; Wang Z; Markel S; Diamond DJ; Luzuriaga K
    J Immunol; 2004 Feb; 172(4):2256-64. PubMed ID: 14764694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants.
    Lacey SF; Gallez-Hawkins G; Crooks M; Martinez J; Senitzer D; Forman SJ; Spielberger R; Zaia JA; Diamond DJ
    Transplantation; 2002 Sep; 74(5):722-32. PubMed ID: 12352893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between cytomegalovirus (CMV) IgG serology, detectable CMV DNA in peripheral monocytes, and CMV pp65(495-503)-specific CD8+ T cells in older adults.
    Leng SX; Qu T; Semba RD; Li H; Yao X; Nilles T; Yang X; Manwani B; Walston JD; Ferrucci L; Fried LP; Margolick JB; Bream JH
    Age (Dordr); 2011 Dec; 33(4):607-14. PubMed ID: 21274637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A simple and efficient method of generating HCMV pp65-specific T cells using overlapping peptides.
    Hwang SU; Lee JH; Choi SY; Lee YT; Park SY; Lee HS; Jae JW; Jung NC; Wang Y; Lim DS
    Acta Virol; 2020; 64(4):470-479. PubMed ID: 33151741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid generation of CMV pp65-specific T cells for immunotherapy.
    Bao L; Sun Q; Lucas KG
    J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects.
    Slezak SL; Bettinotti M; Selleri S; Adams S; Marincola FM; Stroncek DF
    J Transl Med; 2007 Mar; 5():17. PubMed ID: 17391521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
    Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
    Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.